ERBB2 and prostate carcinoma: A recent study in prostate cancer cell lines showed that an HER2/ERBB3 signalling pathway protected the AR from degradation by the ubiquitin–proteasome pathway and enhanced AR transcriptional activity at low androgen concentrations (Mellinghoff et al, 2004).